A US judge dismissed AstraZeneca's request and ruled that companies seeking to launch generic versions of Crestor (rosuvastatin) don't have to include certain uses of the drug on the product's label, Bloomberg reported. AstraZeneca spokesperson Donna Huang said it is "currently reviewing the court’s decision to determine next steps, which may include an appeal."
District judge Robert Kugler said that two patents that cover methods of using the statin, and expire in 2018 and 2022, aren’t required to be added to the product's label by generic drugmakers. Companies that won dismissal of the case included Mylan, Teva, Glenmark, Watson, Apotex, Aurobindo, Par Pharmaceutical, Sun Pharmaceutical, and Torrent Pharmaceuticals. The judge noted that Novartis' Sandoz unit, which wasn't part of the request for dismissal, has the right to file such a request.
Huang remarked that "AstraZeneca has full confidence in its intellectual property protecting Crestor and will continue to aggressively defend the intellectual property protecting the product." In June, a US judge ruled that another patent protecting Crestor was valid and enforceable until 2016. Last year, the product generated $4.5 billion in global sales.
To read more Top Story articles, click here.